Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants
Open accessThe DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index; 31 of the 46 sources its claims cite were checked for support.
Abstract
Metal-dependent histone deacetylases (HDACs) are key epigenetic regulators that represent promising therapeutic targets for the treatment of numerous human diseases. Yet the currently FDA-approved HDAC inhibitors nonspecifically target at least several of the 11 structurally similar but functionally different HDAC isozymes, which hampers their broad usage in clinical settings. Selective inhibitors targeting single HDAC isozymes are being developed, but precise understanding in molecular terms of their selectivity remains sparse. Here, we show that HDAC8-selective inhibitors adopt a L-shaped conformation required for their binding to a HDAC8-specific pocket formed by HDAC8 catalytic tyrosine and HDAC8 L1 and L6 loops. In other HDAC isozymes, a L1-L6 lock sterically prevents L-shaped inhibitor binding. Shielding of the HDAC8-specific pocket by protein engineering decreases potency of HDAC8-selective inhibitors and affects catalytic activity. Collectively, our results unravel key HDAC8 active site structural and functional determinants important for the design of next-generation chemical probes and epigenetic drugs.
Overview
CoChat Summary
## TL;DR
This paper shows that HDAC8-selective inhibitors bind a specific HDAC8 pocket shaped by the catalytic tyrosine and the L1/L6 loops, and that an L-shaped inhibitor conformation is required for this selectivity. The authors combine crystal structures, mutagenesis, biophysical assays, docking, MD, and schistosome assays to show that small changes in inhibitor structure or loop conformation strongly affect potency and selectivity.
## Key findings
- PCI-34051, NCC-149, and Quisinostat (QSN) inhibited hHDAC8 and smHDAC8 in the submicromolar range; the reported IC50 values were 77.7 ± 18.1 nM, 44 ± 4.9 nM, and 64.4 ± 3.4 nM for hHDAC8, and 435.8 ± 61 nM, 95.4 ± 9.3 nM, and 303.4 ± 39 nM for smHDAC8, respectively.
- The crystal structures showed that the HDAC8-selective inhibitors PCI-34051 and NCC-149 adopt an L-shaped conformation and contact the catalytic tyrosine and L6 loop, whereas QSN binds in a more canonical mode.
- HDAC8-selective inhibition was attributed to a specific “HDAC8-selective pocket” formed by the catalytic tyrosine plus L1 and L6 loop residues; in other HDAC isozymes, a L1-L6 lock sterically blocks this pocket.
- Mutating the L1/L6 region reduced activity and weakened inhibition: all mutants had about a 5°C lower Tm than wild type, hHDAC8 mutants showed around 10-fold activity loss in point mutants/L6 replacements, and the triple mutant showed almost no activity; PCI-34051 IC50 increased by more than 64-fold for the triple mutant.
## Methods
- Combined structural, biochemical, and functional analysis of hHDAC8 and smHDAC8, including X-ray crystallography of inhibitor-bound HDAC8 complexes, mutational analysis of L1/L6 loop variants, activity/inhibition assays, ITC, DSF, docking, MD simulations, and parasite culture assays.
- Used recombinant WT and mutant hHDAC8 and smHDAC8 proteins expressed in bacteria; apo smHDAC8 crystals were soaked with inhibitors, and one hHDAC8-mL6/QSN complex structure was obtained by co-crystallization.
- Tested inhibitor effects on S. mansoni schistosomula and adult worms using microscopy-based viability and egg-production assays; schistosomula were treated at 25, 50, and 100 µM, and TUNEL was used to detect DNA strand breaks after 100 µM treatment.
## Limitations
- The authors state that they were not able to obtain well-diffracting crystals of hHDAC8 complexed with PCI-34051, NCC-149, and QSN; only the hHDAC8-mL6/QSN complex yielded exploitable structural data.
- They note that several structures, including QSN bound to hHDAC8-mL6, are influenced by crystal packing, making it difficult to know whether the observed conformations are biologically favored in solution.
- Evident from the text: the mutational analysis was limited by solubility, because all smHDAC8 mutants except point mutants were insoluble, which restricted structural/biophysical follow-up.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 0 Not valid · 6 Not checked · 157 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“we previously observed a very similar binding mode to smHDAC8 for another pan-HDAC inhibitor, M344, including an interaction between D100 and the M344 internal amide group 30”
What the sources say
- Supportedcites [30] matched to “Structural Basis for the Inhibition of Histone Deacetylase 8 (HDAC8), a Key Epigenetic Player in the Blood Fluke Schistosoma mansoni” (2013) source
The “Ligand-induced gating of the catalytic pocket” section describes the smHDAC8–M344 complex and says M344 binding is stabilized by an interaction between its N10 atom and the smHDAC8 D100 carboxylate. The paper also identifies M344 as a generic HDAC inhibitor. Page numbers are not available in the supplied copy. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a similar binding mode was also observed upon SAHA binding to human HDAC2 in a crystal lattice-free environment 39”
What the sources say
- Partly supportedcites [39] matched to “Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability” (2013) sourceExperimental — accuracy not yet measured
The structural-analysis section reports SAHA bound to HDAC2 and describes its binding mode. The crystallization and data-collection section says the structure was determined from crystals soaked with SAHA, so this paper does not support the claim that the observation was made in a crystal lattice-free environment. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In HDAC8, the L1 and L2 loops have been shown to display flexibility, being able to change their conformation to adapt to different inhibitors such as the large Largazole inhibitor and its analogues (Figure S7) 40, 41”
What the sources say
- Partly supportedcites [40] matched to “Structural Basis of the Antiproliferative Activity of Largazole, a Depsipeptide Inhibitor of the Histone Deacetylases” (2011) sourceExperimental — accuracy not yet measured
The discussion of Fig. 3b describes L1 and L2 loop shifts that accommodate bulky largazole thiol and compares some shifts with those seen for another inhibitor, M344. It discusses largazole analogues, but only suggests that one analogue likely triggers a similar change; it does not show L1 and L2 adapting to largazole analogues. (LLM, conf=0.86)
- Supportedcites [41] matched to “Variable Active Site Loop Conformations Accommodate the Binding of Macrocyclic Largazole Analogues to HDAC8” (2015) source
The Discussion states that binding three Largazole analogues triggers changes in HDAC8’s L2 loop that propagate to the L1 loop, and that these changes differ from those in the HDAC8–Largazole complex. The Concluding Remarks likewise describe flexible L1 and L2 loops accommodating Largazole and its analogues. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Previous work on the selective inhibition of smHDAC8 has yielded the development of an inhibitor series of 3-benzamido-benzohydroxamates that show strong selectivity for smHDAC8 and hHDAC8 over other human HDACs 29”
What the sources say
- Supportedcites [29] matched to “Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis” (2016) source
The STRUCTURAL VALIDATION section states that the 3-amido(benzamido)-benzohydroxamates (7a-c, extended to 7d-7z in SYNTHESIS) were active in the nanomolar range and that 'all compounds show specificity for the HDAC8 isoforms over the other human HDACs tested (HDAC1 and 6)', i.e. both smHDAC8 and hHDAC8. CONCLUSIONS repeats that 'the presented compounds demonstrated high selectivity for smHDAC8 over the major human HDAC isoforms HDAC1 and HDAC6, and some compounds even showed a preference for smHDAC8 over its human ortholog hHDAC8', and Table 1 gives the supporting IC50 values. The only qualifier the paraphrase softens is 'tested': the paper's comparison panel is HDAC1 and HDAC6 rather than all human HDACs, which is the paper's own framing. (LLM, conf=0.85)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have previously shown that our smHDAC8 crystals can be used to look at inhibitor binding in a crystal latticeunbiased manner 29, 30, 55-58 .”
What the sources say
- Partly supportedcites [29] matched to “Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis” (2016) sourceExperimental — accuracy not yet measured
Our copy of Heimburg et al. (2016) does demonstrate that smHDAC8 crystals can be used to look at inhibitor binding: native crystals were soaked in mother liquor supplemented with inhibitor 7a (Crystallization and X-ray data collection), and the resulting 2.3 Å smHDAC8/7a complex structure is used to describe the binding mode in the active-site pocket (STRUCTURAL VALIDATION; PDB 5FUE, Structure determination/model building and refinement). However, no passage in our copy characterises these crystals as permitting binding to be observed 'in a crystal lattice-unbiased manner' — the paper only notes that the complex crystals share the native crystals' space group (P1) and unit cell, and nowhere comments on lattice effects or their absence. That methodological qualifier is therefore attributed to this source without support from it. (LLM, conf=0.70)
- Partly supportedcites [30] matched to “Structural Basis for the Inhibition of Histone Deacetylase 8 (HDAC8), a Key Epigenetic Player in the Blood Fluke Schistosoma mansoni” (2013) sourceExperimental — accuracy not yet measured
The ‘Structure-guided design of specific inhibitors’ section (page unavailable) reports that soaking smHDAC8 crystals yielded structures showing how J1038 and J1075 bind. The paper does not establish that the observed binding is unbiased by the crystal lattice, so that qualification is unsupported. (LLM, conf=0.84)
- Partly supportedcites [55] matched to “Synthesis, Crystallization Studies, and in vitro Characterization of Cinnamic Acid Derivatives as Sm HDAC8 Inhibitors for the Treatment of Schistosomiasis” (2018) sourceExperimental — accuracy not yet measured
Our copy does show these SmHDAC8 crystals being used to examine inhibitor binding: four SmHDAC8/inhibitor complexes were soaked, solved and refined (Crystallization and X-ray data collection; Structure determination, model building and refinement), and the complexes 'belonged to the same space group (P1) and had the same unit cell as native SmHDAC8 crystals'. The Structure-activity relationship and structural validation section reports binding 'in different orientations in the active site pocket' with both flipped-in and flipped-out Phe151 in the 9b structure, and the Docking study confirms binding 'reminiscent of our previous crystallographic analyses'. However, no passage in our copy (searched: 'lattice-unbiased', 'crystal packing', 'low symmetry P1 not constraining binding', 'soaking/native comparison') states or argues that this lattice permits assessment of inhibitor binding free of crystal-lattice bias — that methodological qualifier is the part attributed to this source that it does not support. (LLM, conf=0.68)
- Not checked — no full text of the sourcecites [56] matched to “Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity” (2017) source
- Partly supportedcites [57] matched to “A Novel Class of Schistosoma mansoni Histone Deacetylase 8 (HDAC8) Inhibitors Identified by Structure-Based Virtual Screening and In Vitro Testing” (2018) sourceExperimental — accuracy not yet measured
Section 2.2 (page unavailable) reports an smHDAC8–J1036 crystal structure and describes the inhibitor’s binding in the active-site pocket. Section 3.4 (page unavailable) describes soaking smHDAC8 crystals with J1036. Neither section establishes that the observed binding is unbiased by crystal-lattice contacts. (LLM, conf=0.84)
- Partly supportedcites [58] matched to “Molecular Basis for the Antiparasitic Activity of a Mercaptoacetamide Derivative That Inhibits Histone Deacetylase 8 (HDAC8) from the Human Pathogen Schistosoma mansoni” (2014) sourceExperimental — accuracy not yet measured
Our copy of Stolfa et al. (2014) does use smHDAC8 crystals to examine inhibitor binding: the section 'Crystal structure of smHDAC8 in complex with the mercaptoacetamide inhibitor 1a' reports a 2.3 A co-crystal in which 1a 'binds to each monomer in the asymmetric unit of the crystal with full occupancy' with well-defined, unambiguously interpretable density in the catalytic pocket (zinc ion and Y341), and 'Structure determination, model building and refinement' notes the complex crystallizes in the same space group (P1) and unit cell as native smHDAC8. However, no passage in our copy addresses the 'crystal lattice-unbiased' qualifier: searches for crystal lattice, packing or lattice-contact effects returned nothing that comments on whether the lattice constrains or biases the observed binding mode (the only per-monomer detail given is variable C-C-S-Zn dihedral angles: 28.4, 26.8, -17.0 and 13.5). So the source supports the general point that smHDAC8 co-crystals reveal inhibitor binding, but not the specific methodological claim of lattice-independent/unbiased observation asserted in the citing sentence. (LLM, conf=0.66)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
95 more claims
Create a free account to see all 177 claims and to verify the 4 references still open.
- It may state two separate claims as one. 62
- Probably not a substantial claim. 17
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Particle mesh Ewald: An N ⋅log( N ) method for Ewald sums in large systems
Darden, T., York, D., & Pedersen, L. (1993) · The Journal of Chemical Physics · doi:10.1063/1.464397 · Cited by 30,546
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Ryckaert, J.-P., Ciccotti, G., & Berendsen, H. J. C. (1977) · Journal of Computational Physics · doi:10.1016/0021-9991(77)90098-5 · Cited by 21,239
Development and testing of a general amber force field
Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20035 · Cited by 19,506
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
The missing term in effective pair potentials
Berendsen, H. J. C., Grigera, J. R., & Straatsma, T. P. (1987) · The Journal of Physical Chemistry · doi:10.1021/j100308a038 · Cited by 13,345
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
Duan, Y., Wu, C., Chowdhury, S., Lee, M. C., Xiong, G., Zhang, W., Yang, R., Cieplak, P., Luo, R., Lee, T., et al. (2003) · Journal of Computational Chemistry · doi:10.1002/jcc.10349 · Cited by 4,441
Jakalian, A., Jack, D. B., & Bayly, C. I. (2002) · Journal of Computational Chemistry · doi:10.1002/jcc.10128 · Cited by 3,426
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Foloppe, N., & MacKerell, Jr. (2000) · Journal of Computational Chemistry · doi:10.1002/(sici)1096-987x(20000130)21:2<86::aid-jcc2>3.0.co;2-g · Cited by 1,582
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · cited 1×
“We have used another benzohydroxamate inhibitor (11) which has an internal amine rather than an”
MethodNew and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
The growing landscape of lysine acetylation links metabolism and cell signalling
Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E., & Mann, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3841 · Cited by 1,324 · cited 1×
“The structure of smHDAC8 with the simplest inhibitor of this series (1) revealed that”
BackgroundTargeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond
Verdin, E., & Ott, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3931 · Cited by 877
Perceiving the epigenetic landscape through histone readers
Musselman, C. A., Lalonde, M.-E., Côté, J., & Kutateladze, T. G. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2436 · Cited by 833
The world of protein acetylation
Drazic, A., Myklebust, L. M., Ree, R., & Arnesen, T. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.06.007 · Cited by 804
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638
Writers and Readers of Histone Acetylation: Structure, Mechanism, and Inhibition
Marmorstein, R., & Zhou, M.-M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018762 · Cited by 638
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle
Deardorff, M. A., Bando, M., Nakato, R., Watrin, E., Itoh, T., Minamino, M., Saitoh, K., Komata, M., Katou, Y., Clark, D., et al. (2012) · Nature · doi:10.1038/nature11316 · Cited by 577
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition
Hai, Y., & Christianson, D. W. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2134 · Cited by 521
Structure of Hdac3 Bound to Co-Repressor and Inositol Tetraphosphate
Watson, P. J., Fairall, L., Santos, G. M., & Schwabe, J. W. R. (2012) · Nature · doi:10.1038/nature10728 · Cited by 505
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
Taking into Account the Ion-Induced Dipole Interaction in the Nonbonded Model of Ions
Li, P., & Merz, K. M. (2014) · Journal of Chemical Theory and Computation · doi:10.1021/ct400751u · Cited by 436
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates
Millard, C. J., Watson, P. J., Celardo, I., Gordiyenko, Y., Cowley, S. M., Robinson, C. V., Fairall, L., & Schwabe, J. W. R. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.05.020 · Cited by 396
Ramalho-Pinto, F. J., Gazzinelli, G., Howells, R. E., Mota-Santos, T. A., Figueiredo, E. A., & Pellegrino, J. (1974) · Experimental Parasitology · doi:10.1016/0014-4894(74)90076-9 · Cited by 368
Structural insights into HDAC6 tubulin deacetylation and its selective inhibition
Miyake, Y., Keusch, J. J., Wang, L., Saito, M., Hess, D., Wang, X., Melancon, B. J., Helquist, P., Gut, H., & Matthias, P. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2140 · Cited by 315
HDAC8: a multifaceted target for therapeutic interventions
Chakrabarti, A., Oehme, I., Witt, O., Oliveira, G., Sippl, W., Romier, C., Pierce, R. J., & Jung, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.013 · Cited by 284
Self-citationVannini, A., Volpari, C., Gallinari, P., Jones, P., Mattu, M., Carfí, A., De Francesco, R., Steinkühler, C., & Di Marco, S. (2007) · The EMBO Reports · doi:10.1038/sj.embor.7401047 · Cited by 256
Insights into the activation mechanism of class I HDAC complexes by inositol phosphates
Watson, P. J., Millard, C. J., Riley, A. M., Robertson, N. S., Wright, L. C., Godage, H. Y., Cowley, S. M., Jamieson, A. G., Potter, B. V. L., & Schwabe, J. W. R. (2016) · Nature Communications · doi:10.1038/ncomms11262 · Cited by 244
Arts, J., King, P., Marin, A., Floren, W., Belin, A., Janssen, L., Pilatte, I., Roux, B., Decrane, L., Gilissen, R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0547 · Cited by 224
Dowling, D. P., Gantt, S. L., Gattis, S. G., Fierke, C. A., & Christianson, D. W. (2008) · Biochemistry · doi:10.1021/bi801610c · Cited by 200
Histone deacetylase 10 structure and molecular function as a polyamine deacetylase
Hai, Y., Shinsky, S. A., Porter, N. J., & Christianson, D. W. (2017) · Nature Communications · doi:10.1038/ncomms15368 · Cited by 200
Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors
KrennHrubec, K., Marshall, B. L., Hedglin, M., Verdin, E., & Ulrich, S. M. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.064 · Cited by 192
Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors
Porter, N. J., Mahendran, A., Breslow, R., & Christianson, D. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718823114 · Cited by 190
Marek, M., Kannan, S., Hauser, A.-T., Moraes Mourão, M., Caby, S., Cura, V., Stolfa, D. A., Schmidtkunz, K., Lancelot, J., Andrade, L., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003645 · Cited by 173
Self-citationSuzuki, T., Ota, Y., Ri, M., Bando, M., Gotoh, A., Itoh, Y., Tsumoto, H., Tatum, P. R., Mizukami, T., Nakagawa, H., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300837y · Cited by 165
Self-citationWhitehead, L., Dobler, M. R., Radetich, B., Zhu, Y., Atadja, P. W., Claiborne, T., Grob, J. E., McRiner, A., Pancost, M. R., Patnaik, A., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.030 · Cited by 164
Diebold, M.-L., Fribourg, S., Koch, M., Metzger, T., & Romier, C. (2011) · Journal of Structural Biology · doi:10.1016/j.jsb.2011.02.001 · Cited by 160
Self-citationKaiser, F. J., Ansari, M., Braunholz, D., Concepción Gil-Rodríguez, M., Decroos, C., Wilde, J. J., Fincher, C. T., Kaur, M., Bando, M., Amor, D. J., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu002 · Cited by 154
Bürli, R. W., Luckhurst, C. A., Aziz, O., Matthews, K. L., Yates, D., Lyons, K. A., Beconi, M., McAllister, G., Breccia, P., Stott, A. J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4011884 · Cited by 153
Cole, K. E., Dowling, D. P., Boone, M. A., Phillips, A. J., & Christianson, D. W. (2011) · Journal of the American Chemical Society · doi:10.1021/ja205972n · Cited by 153
Cancer epigenetics drug discovery and development: the challenge of hitting the mark
Campbell, R. M., & Tummino, P. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71605 · Cited by 149
Dubois, F., Caby, S., Oger, F., Cosseau, C., Capron, M., Grunau, C., Dissous, C., & Pierce, R. J. (2009) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2009.06.001 · Cited by 129
Self-citationHeimburg, T., Chakrabarti, A., Lancelot, J., Marek, M., Melesina, J., Hauser, A.-T., Shaik, T. B., Duclaud, S., Robaa, D., Erdmann, F., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01478 · Cited by 124
Self-citationVenugopal, B., Baird, R., Kristeleit, R. S., Plummer, R., Cowan, R., Stewart, A., Fourneau, N., Hellemans, P., Elsayed, Y., Mcclue, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0312 · Cited by 122
Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases
Chakrabarti, A., Melesina, J., Kolbinger, F. R., Oehme, I., Senger, J., Witt, O., Sippl, W., & Jung, M. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0117 · Cited by 111
Self-citationPorter, N. J., Osko, J. D., Diedrich, D., Kurz, T., Hooker, J. M., Hansen, F. K., & Christianson, D. W. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01013 · Cited by 111
Heimburg, T., Kolbinger, F. R., Zeyen, P., Ghazy, E., Herp, D., Schmidtkunz, K., Melesina, J., Shaik, T. B., Erdmann, F., Schmidt, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01447 · Cited by 92
Self-citationOn the inhibition of histone deacetylase 8
Estiu, G., West, N., Mazitschek, R., Greenberg, E., Bradner, J. E., & Wiest, O. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.080 · Cited by 82
Dowling, D. P., Gattis, S. G., Fierke, C. A., & Christianson, D. W. (2010) · Biochemistry · doi:10.1021/bi1005046 · Cited by 81
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4579 · Cited by 78
Stolfa, D. A., Marek, M., Lancelot, J., Hauser, A.-T., Walter, A., Leproult, E., Melesina, J., Rumpf, T., Wurtz, J.-M., Cavarelli, J., et al. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.03.007 · Cited by 75
Self-citationInnovative Strategies for Selective Inhibition of Histone Deacetylases
Maolanon, A. R., Madsen, A. S., & Olsen, C. A. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.06.011 · Cited by 72
Suzuki, T., Muto, N., Bando, M., Itoh, Y., Masaki, A., Ri, M., Ota, Y., Nakagawa, H., Iida, S., Shirahige, K., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300414 · Cited by 71
Self-citationChidamide in the treatment of peripheral T-cell lymphoma
Chan, T., Tse, E., & Kwong, Y.-L. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s93528 · Cited by 69
General Base–General Acid Catalysis in Human Histone Deacetylase 8
Gantt, S. M. L., Decroos, C., Lee, M. S., Gullett, L. E., Bowman, C. M., Christianson, D. W., & Fierke, C. A. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01327 · Cited by 67
Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6
Porter, N. J., Wagner, F. F., & Christianson, D. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00367 · Cited by 64
Dasgupta, T., Antony, J., Braithwaite, A. W., & Horsfield, J. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.704627 · Cited by 62
Lopez, G., Bill, K. L. J., Bid, H. K., Braggio, D., Constantino, D., Prudner, B., Zewdu, A., Batte, K., Lev, D., & Pollock, R. E. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133302 · Cited by 60
Tabackman, A. A., Frankson, R., Marsan, E. S., Perry, K., & Cole, K. E. (2016) · Journal of Structural Biology · doi:10.1016/j.jsb.2016.06.023 · Cited by 60
Decroos, C., Clausen, D. J., Haines, B. E., Wiest, O., Williams, R. M., & Christianson, D. W. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00010 · Cited by 58
Vanderstraete, M., Gouignard, N., Cailliau, K., Morel, M., Lancelot, J., Bodart, J., & Dissous, C. (2013) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002226 · Cited by 52
Self-citationAlterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer
Hsieh, C.-L., Ma, H.-P., Su, C.-M., Chang, Y.-J., Hung, W.-Y., Ho, Y.-S., Huang, W.-J., & Lin, R.-K. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.02.092 · Cited by 47
Simoben, C., Robaa, D., Chakrabarti, A., Schmidtkunz, K., Marek, M., Lancelot, J., Kannan, S., Melesina, J., Shaik, T., Pierce, R., et al. (2018) · Molecules · doi:10.3390/molecules23030566 · Cited by 44
Self-citationDeardorff, M. A., Porter, N. J., & Christianson, D. W. (2016) · Protein Science · doi:10.1002/pro.3030 · Cited by 37
Porter, N. J., Christianson, N. H., Decroos, C., & Christianson, D. W. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b01014 · Cited by 33
HDAC8 functions in spindle assembly during mouse oocyte meiosis
Zhang, K., Lu, Y., Jiang, C., Liu, W., Shu, J., Chen, X., Shi, Y., Wang, E., Wang, L., Hu, Q., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15383 · Cited by 27
Bayer, T., Chakrabarti, A., Lancelot, J., Shaik, T. B., Hausmann, K., Melesina, J., Schmidtkunz, K., Marek, M., Erdmann, F., Schmidt, M., et al. (2018) · ChemMedChem · doi:10.1002/cmdc.201800238 · Cited by 23
Self-citationRamos, T. L., Sánchez-Abarca, L. I., Redondo, A., Hernández-Hernández, Á., Almeida, A. M., Puig, N., Rodríguez, C., Ortega, R., Preciado, S., Rico, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15969 · Cited by 13
Marek, M., Shaik, T. B., Duclaud, S., Pierce, R. J., & Romier, C. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3667-0_8 · Cited by 5
Self-citationVannini, A., Volpari, C., Gallinari, P., Jones, P., Mattu, M., Carfí, A., Defrancesco, R., Steinkühler, C., & Marco, S. D. (2007) · doi:10.2210/pdb2v5w/pdb · Cited by 4
Bürli, R., Luckhurst, C., Aziz, O., Matthews, K., Yates, D., Lyons, K., Beconi, M., Mcallister, G., Breccia, P., Stott, A., et al. (2013) · doi:10.2210/pdb4cbt/pdb
Cancer epigenetics drug discovery and development: the challenge of hitting the mark
Campbell, R. M., & Tummino, P. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75448
Cited by
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
Zhao, C., Dong, H., Xu, Q., & Zhang, Y. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1725470 · Cited by 147
“amino acid residues at the solvent-exposed region of the enzyme [5,22,23].”
BackgroundNext-generation of selective histone deacetylase inhibitors
Yang, F., Zhao, N., Ge, D., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra02985k · Cited by 155
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Self-citationHistone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview
Banerjee, S., Adhikari, N., Amin, S. A., & Jha, T. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.039 · Cited by 108
Metadata
- Authors
- Marek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., Schmidtkunz, K., Suzuki, T., Holl, R., Ennifar, E., Pierce, R. J., Jung, M., Sippl, W., & Romier, C.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Martin Luther University Halle-Wittenberg (DE)
- University of Freiburg (DE)
- Institut de Génétique et Biologie Moléculaire et Cellulaire (IGBMC), Département de Biologie Structurale Intégrative, Université de Strasbourg, Centre National de la Recherche Scientifique (CNRS UMR7104), Institut National de la Santé et de la Recherche Médicale (INSERM U1258), 1 rue Laurent Fries, 67404 Illkirch Cedex, France
- University of Münster (DE)
- Kyoto Prefectural University of Medicine (JP)
- Universität Hamburg (DE)
- Corresponding author
- Marek, Martin
- Romier, Christophe
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-10-22
- Volume
- 61
- Issue
- 22
- Pages
- 10000-10016
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2897192913
- Cited by
- 122
- References
- 80
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 16 · 2023: 14 · 2022: 19 · 2021: 16 · 2020: 18 · 2019: 10 · 2018: 1
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- green
- cnrs.hal.science
- Licence
- other-oa
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0030-INRT, ANR-10-IDEX-0002-02)
- Deutsche Forschungsgemeinschaft (Si868/13-1, Ju295/13-1)
- Seventh Framework Programme (241865, 602080)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- HDAC8, catalytic tyrosine, protein engineering, epigenetic drug design, chemical probes, epigenetic regulators
- MeSH terms
- Amino Acid Sequence, Histone Deacetylases, Humans, Hydroxamic Acids, Indoles, Repressor Proteins, Structure-Activity Relationship, Substrate Specificity, Triazoles, Catalytic Domain, Molecular Dynamics Simulation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.